New Approaches to the Pathogenesis and Treatment of Diabetic Microangiopathy

Diabetic Medicine

Volumn 5, Issue 2, 1988, Pages 111-117

  Jennings, P E ^a,b   Barnett, A H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Aldose reductase; Basement membrane thickening; Diabetic microangiopathy; Free radicals Antioxidants; Genetic susceptibility; Non enzymatic glycosylation; Prostaglandins

Indexed keywords

FREE RADICAL;

DIABETES MELLITUS; ENDOTHELIUM; HUMAN; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW;

ANTIOXIDANTS; BASEMENT MEMBRANE; BLOOD PLATELETS; BLOOD VESSELS; CAPILLARIES; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE; FREE RADICALS; GENETIC PREDISPOSITION TO DISEASE; GLYCOSYLATION; HUMAN; PROSTAGLANDINS; SUPPORT, NON-U.S. GOV'T; THERAPEUTICS;

EID: 0023833906     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.1988.tb00955.x     Document Type: Review

References (78)

1. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973
2. Relation of diabetic control to development of microvascular complications
3. Complications of diabetes mellitus: relationship to metabolic dysfunction
4. Diabetic control and microvascular complications: the near‐normoglycaemic experience
5. The microcirculation in diabetes
6. Prognosis of diabetics with diabetes onset before age of 31
7. Metabolic control and vascular disease in diabetes mellitus
8. Diabetic retinopathy in identical twins
9. Diabetic retinopathy in identical twins
10. Immunogenetics of diabetic microangiopathy
11. The genetics of diabetic complications
12. Relation of gene expression (allotypes) of the fourth component of complement to insulin dependent diabetes and its microangiopathic complications
13. Immunoglobulin heavy chain phenotypes in diabetic microangiopathy—evience for an immunogenetic predisposition
14. Blind alleys in diabetes research: muscle capillary basement membrane thickening: marker of microvascular complications or false prophet
15. Search for a biochemical basis of diabetic microangiopathy
16. Studies on the human glome‐rular basement membrane. Composition, nature of the carbohydrate units and chemical changes in diabetes mellitus
17. Biochemical properties of human glomerular basement membrane in normal and diabetic kidneys
18. Partial characterization of newly synthesized proteoglycans isolated from the glomerular basement membrane
19. Anionic sites in the glomerular basement membrane
20. Connective tissue in diabetes mellitus: biochemical alterations of the intracellular matrix with special reference to proteoglycan, collagens and basement membranes
21. Glycosylation of human glomerular basement membrane collagen: increased content of hexose in ketoamine linkage and unaltered hydroxylysine‐o‐glycosides in patients with diabetes
22. Chemistry of non‐enzymatic browning
23. Covalent attachment of soluble proteins by non enzymatically glycosylated collagen: role of in situ formation of immune complexes
24. Non enzymatic glycosylation and the pathogenesis of diabetic complications
25. Relation between complications of type 1 diabetes mellitus and collagen‐linked fluorescence
26. Aging of proteins isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose
27. Investigation of human plasma low density lipoprotein by three dimensional fluorescence spectro‐scopy
28. Synthesis and characterisation of the fluorescent products derived from malonylaldehyde and amino acids
29. Fluorescence changes in human gamma‐globulin induced by free radical activity
30. Free radical mediated aggregation of human gamma globulin
31. Fluorometric study of tryptophan photolysis
32. Protein browning and diabetic complications
33. Inhibitory effect of superoxide dismutase on fructosamine assay
34. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients
35. Increased lipoperoxide value and glutathione peroxidase activity in blood plasma of type II (non‐insulin dependent) diabetic women
36. Increased diene conjugates in diabetic subjects with microangiopathy
37. Prostaglandin biosynthesis can be triggered by lipid peroxides
38. Lipid peroxidation in relation to prostacyclin and thromboxane physiology and pathophysiology
39. Peroxidase dependent deactivation of prostacyclin synthetase
40. Glutathione and its redox system in diabetic polymorphonuclear leucocytes
41. Plasma ascorbate concentrations and blood cell dehydro ascorbate transport in patients with diabetes mellitus
42. Vitamin C metabolites and microangiopathy in diabetes mellitus
43. Production of 12 HETE and vitamin E status in platelets from type 1 human diabetic subjects
44. Aldose reductase and complications of diabetes
45. Early retinal microangiopathy: prevention with aldose reductase inhibitors
46. Aldose reductase inhibition, glomerular metabolism and diabetic nephropathy
47. The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase
48. The effect of an aldose reductase inhibitor (Sorbinil) on the level of metabolites in the lenses of diabetic rats
49. The effect of oxidation on Sorbitol pathway kinetics
50. Evidence for functional endothelial cell damage in early diabetic retinopathy
51. 2 release in normal and diabetic rats by the antithrombotic compound BAYg 6575
52. Circulating prostacyclin may be reduced in diabetes
53. Fibrinolysis and diabetic retinopathy
54. Haemostatic variables associated with diabetes and its complications
55. Diabetic retinopathy and the fibrinolytic system
56. Angiotensin converting enzyme. Vascular endothelial localisation
57. Serum angiotension converting enzyme; elevations in diabetes mellitus
58. Angiotensin‐converting enzyme (ACE): relationship to insulin dependent diabetes and microangiopathy
59. Increased angiotension‐converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease
60. 2 by diabetic platelets
61. Thromboxane biosynthesis in platelets of diabetic and coronary artery diseased patients
62. Phospholipase activity and plasma membrane homeostasis
63. Platelet factor 4 release during human platelet aggregation in diabetic patients
64. Platelet alpha granule release in diabetes mellitus
65. Some characteristics of spontaneous platelet aggregation in young insulin dependent diabetic subjects
66. Platelet aggregation and coagulation factors in insulin dependent diabetics with and without micro‐angiopathy
67. Interactions of platelet factor 4 and the glycosaminoglycans
68. Insulin‐like growth factors in vitreous. Studies in control and diabetic subjects with neovascularisation
69. Aminoguanidine prevents diabetes‐induced arterial wall protein cross‐linking
70. Potential clinical applications for high dose nutritional antioxidants
71. Rationales for micronutrient supplementation in diabetes
72. Hypothesis: The role of vitamin C in diabetic angiopathy
73. Proposed metabolic dysfunction in diabetic microthromboses and microangiopathy
74. Diabetic retinopathy and rheumatoid arthritis
75. Specific thromboxane synthetase inhibition and albumin excretion rate in insulin dependent diabetes
76. Action of Sorbinil in diabetic peripheral nerve. Relation of polyol (Sorbitol) pathway inhibition to a myo‐inositol‐mediated defect in sodium‐potassium ATPase activity